On 25 December 2018, the MGI Sequencing Summit China 2018 was successfully held in Shanghai. The conference brought together experts from the industry, sharing insights around topics such as omics research, cancer detection, and the latest developments and innovations in sequencing technology. The showcase of MGISEQ-T7 also made a splash during the conference.
In the Academician Forum, Dr Yang Huanming, Chairman of BGI group, and Prof Ning Guang, academician of the Chinese Academy of Engineering, had an in-depth discussion on the current situation, future directions, and challenges to be addressed in the development of omics research, based on their own experiences.
Jiang Hui, Chief Operating Officer of MGI, introduced MGISEQ-T7, MGI’s most powerful genetic sequencer to date. Professor Shi Yongyong, Bio-X Institutes of Shanghai Jiaotong University, presented the application of high-throughput sequencing in rare diseases. He shared that the data generated from MGISEQ-2000 has very satisfying quality in his research group. Professor Xin Changpeng, Bio-Med Big Data Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, shared with the guests the National Omics Data Encyclopedia (NODE), a new omics data management platform. He also shared RNA-seq data generated on MGISEQ-2000, which had good performance with Q30>90%. Dr Chen Gang, founder and CEO of WeGene, introduced the DTC market in China and abroad, the regulatory situation, and the future directions of development. He announced that based on MGI’s sequencing platforms, WeGene has delivered over 1000 DTC WGS.
The afternoon forum focused on sequencing applications for cancer research and the latest research progress in NGS technology. Xu Xiaohong, co-founder and technical director of Gloriagene, presented and shared their good results of prostate cancer panel tests based on the MGISEQ-2000 platform. Chen Haiyan, R&D director of Suzhou Gene+, introduced the Gene+Seq series high-throughput genetic sequencers and their performance in clinical cancer gene detection, based on DNBSeqTM sequencing technology. Li Mingjie, from CWBIO, showed that MGISEQ-2000 performed well in both multiple PCR and liquid-phase hybridization. Dr Wang Tingting, from REALBIO Technology, presented their studies on how metagenomics sheds light on cancer medication guidance. In their research project, the MGISEQ platform generated high-quality data with a low duplicate rate. Dr Ling Shaoping, CEO and Chief Scientist of Genowis, announced that Genowis and MGI will collaborate in developing a total package for WES-based immunological genomes.
Dr Chen Fang, from BGI Research, introduced the disruptive stLFR technology released in ICG-13 in Shenzhen in October, and its recent application progress towards perfect genome studies. Dr Han Jinxiong, from Vazyme Biotech, introduced the development of library preparation reagent kits based on the MGI sequencing platform. Dr Zheng Wenli, from Nanodigmbio, presented their development of a total package of targeted sequencing based on the MGI sequencing platform.
